Abstract

Transcutaneous immunization (TCI) via needle-free and non-invasive drug delivery systems is a promising approach for overcoming the current limitations of conventional parenteral vaccination methods. The targeted access to professional antigen-presenting cell (APC) populations within the skin, such as Langerhans cells (LCs), various dermal dendritic cells (dDCs), macrophages, and others makes the skin an ideal vaccination site to specifically shape immune responses as required. The stratum corneum (SC) of the skin is the main penetration barrier that needs to be overcome by the vaccine components in a coordinated way to achieve optimal access to dermal APC populations that induce priming of T-cell or B-cell responses for protective immunity. While there are numerous approaches to penetrating the SC, such as electroporation, sono- or iontophoresis, barrier and ablative methods, jet and powder injectors, and microneedle-mediated transport, we will focus this review on the recent progress made in particle-based systems for TCI. This particular approach delivers vaccine antigens together with adjuvants to perifollicular APCs by diffusion and deposition in hair follicles. Different delivery systems including nanoparticles and lipid-based systems, for example, solid nano-emulsions, and their impact on immune cells and generation of a memory effect are discussed. Moreover, challenges for TCI are addressed, including timely and targeted delivery of antigens and adjuvants to APCs within the skin as well as a deeper understanding of the ill-defined mechanisms leading to the induction of effective memory responses.

Highlights

  • The skin is the outer barrier of our body that executes a plethora of essential functions, including maintenance of fluids, regulation of body temperature, sensing of pain, and sheltering from external aggressors

  • We developed nano-dispersed imiquimod formulations together with the synthetic peptide SIINFEKL and compared them for their vaccination potency against the commercially available imiquimod formulation Aldara R [71, 72]

  • Particle-based systems have great potential for transcutaneous vaccine delivery via the skin. Their active skin delivery can enhance vaccine immunogenicity due to achieving better particulate antigen-presenting cells (APC) recognition and activation compared to soluble antigens

Read more

Summary

INTRODUCTION

The skin is the outer barrier of our body that executes a plethora of essential functions, including maintenance of fluids, regulation of body temperature, sensing of pain, and sheltering from external aggressors. Interesting for vaccination via the skin are the unique, but heterogeneous populations of professional antigen-presenting cells (APC) located in the viable epidermis and the dermis, respectively. Dermal DCs represent a highly mixed subset with functional heterogeneity and have been identified as key players in the induction of immune responses both in cutaneous infection and in skin vaccination [6]. Based on their developmental origin, surface markers, and function, dDCs can be broadly subdivided in steady-state conditions. The ideal targeting of cutaneous APC populations by a skin-compatible adjuvant agent appears to be indispensable for the induction of a powerful adaptive immune response and the initiation of immunological memory.

Active Delivery Methods
Active particulate delivery
Passive particulate delivery
Passive Delivery Methods
CONCLUSION
Findings
AUTHOR CONTRIBUTIONS
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call